Pharma BD Deal Intelligence

Genzyme Corporation (Genzyme Biosurgery) / Biomatrix Inc.

2000 · Acquisition/Merger · $700M · Complete

Announcement Sentiment

Neutral / mixed

Genzyme acquired Biomatrix in a cash-and-stock deal valued at ~$700M (cash component ~$245M at $37/share for 28.4% of shares, stock for the balance). Combined with Genzyme Tissue Repair and Genzyme Surgical Products to create Genzyme Biosurgery tracking-stock entity. Closed Dec 18, 2000.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 15yr post-close.

Key facts

Announced Sep 06, 2000
Closed Dec 18, 2000
Deal value $700M
Deal type Acquisition/Merger
Therapeutic area Knee osteoarthritis
Indications Knee osteoarthritis
Key assets Synvisc (hylan G-F 20)
Mechanism Viscosupplementation (cross-linked hyaluronic acid)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals